Skip to content
10-Q

Quarterly Report

PALISADE BIO, INC. PALI

0001357459-26-000010

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 173.58M sh
Shares Diluted Q1 2026 · Mar 31, 2026 209.66M sh
Shares Diluted Q1 2026 · Mar 31, 2025 4.8M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.33M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $132.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $133.39M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $7.23M
Stockholders Equity Q1 2026 · Mar 31, 2026 $127.36M
Stockholders Equity Q1 2026 · Dec 31, 2025 $129.38M
Stockholders Equity Q1 2026 · Mar 31, 2025 $5.33M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.49M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.62M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.64M
Total Liabilities Q1 2026 · Mar 31, 2026 $5.95M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.96M
Current Assets Q1 2026 · Mar 31, 2026 $133.24M
Current Assets Q1 2026 · Dec 31, 2025 $134.22M
Total Assets Q1 2026 · Mar 31, 2026 $133.32M
Total Assets Q1 2026 · Dec 31, 2025 $134.34M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.05
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.47
Eps Basic Q1 2026 · Mar 31, 2026 −$0.05
Eps Basic Q1 2026 · Mar 31, 2025 −$0.47
Rd Expense Q1 2026 · Mar 31, 2026 $6M
Net Income Q1 2026 · Mar 31, 2026 −$9.6M
Net Income Q1 2026 · Mar 31, 2025 −$2.23M
Operating Income Q1 2026 · Mar 31, 2026 −$10.75M
Operating Income Q1 2026 · Mar 31, 2025 −$2.31M